Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

Javier Zulueta, MD
Published: Tuesday, Jun 06, 2017



Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.

This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.
 
SELECTED
LANGUAGE


Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

An additional application for the test is to detect dysplasia, states Zulueta. There is now evidence that chemo-prevention can be achieved in patients who have dysplasia.

This has been shown in phase II trials, explains Zulueta. Previously, in order to diagnose dysplasia there was an invasive test, however, now the LuCED test can provide a non-invasive diagnosis.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x